Effect of insulin degludec versus insulin glargine U100 on time in range: SWITCH PRO , a crossover study of basal insulin‐treated adults with type 2 diabetes and risk factors for hypoglycaemia

Utility of Real-Time and Retrospective Continuous Glucose Monitoring in Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials

(2019) Satoshi Ida et al.   Journal of Diabetes Research

Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range

(2019) Tadej Battelino et al.   DIABETES CARE

The Association of Hypoglycemia Assessed by Continuous Glucose Monitoring With Cardiovascular Outcomes and Mortality in Patients With Type 2 Diabetes

(2019) Wei Wei et al.   Frontiers in Endocrinology

6. Glycemic Targets: Standards of Medical Care in Diabetes—2020

(2019)   DIABETES CARE

Interference Assessment of Various Endogenous and Exogenous Substances on the Performance of the Eversense Long-Term Implantable Continuous Glucose Monitoring System

(2018) Carrie Lorenz et al.   Diabetes Technology & Therapeutics

Detection of asymptomatic drug-induced hypoglycemia using continuous glucose monitoring in older people – Systematic review

(2018) K. Mattishent et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

Flash Glucose Monitoring: A Review of the Literature with a Special Focus on Type 1 Diabetes

(2018) Giulia Mancini et al.   Nutrients

The Relationship of Hemoglobin A1C to Time-in-Range in Patients with Diabetes

(2018) Robert A. Vigersky et al.   Diabetes Technology & Therapeutics

Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes

(2017) Carol Wysham et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes

(2017) Wendy Lane et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes

(2017) Steven P. Marso et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of ethnicity on HbA1c levels in individuals without diabetes: Systematic review and meta-analysis

(2017) Gabriela Cavagnolli et al.   PLoS One

Glucose Concentrations of Less Than 3.0 mmol/L (54 mg/dL) Should Be Reported in Clinical Trials: A Joint Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes: Table 1

(2016)   DIABETES CARE

The Performance and Usability of a Factory-Calibrated Flash Glucose Monitoring System

(2015) Timothy Bailey et al.   Diabetes Technology & Therapeutics

World Medical Association Declaration of Helsinki

(2013)   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes: A 1-year, randomized, treat-to-target trial (BEGIN Once Long)

(2012) B. Zinman et al.   DIABETES CARE

Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials

(2012) R. E. Ratner et al.   DIABETES OBESITY & METABOLISM

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

(2012) Alan J Garber et al.   LANCET

Effect of Continuous Glucose Monitoring on Hypoglycemia in Type 1 Diabetes

(2011) T. Battelino et al.   DIABETES CARE

Relationship between Clinical Markers of Glycemia and Glucose Excursion Evaluated by Continuous Glucose Monitoring (CGM).

(2010) Tomoko SUWA et al.   ENDOCRINE JOURNAL